AIM: £2.87 (-0.07) | Nasdaq: $18.29 (-0.20)

Search

EN
简
繁

About Us
Innovation Platform
Commercial Platform
News & Presentations
Financial Results
Shareholder Information
Careers

EN
简
繁

About Us

Overview
Corporate Information
Board of Directors
Senior Management
Contact Us

Innovation Platform

Overview
R&D Approach
Our Pipeline
Key Corporate Partnerships
Innovation News

Commercial Platform

Overview
Competitive Advantages
Prescription Drugs
Consumer Health
Main Products
Commercial Platform News

News & Presentations

Recent News
All RNS & Press Releases
Presentations & Publications

Financial Results

Overview
Chairman's Statement
Financial Highlights
Financial Reports
SEC Filings

Shareholder Information

Overview
Events, Circulars & Forms
Share Price & Chart
Major Shareholders
Analyst Coverage
Dual-listing FAQs
Information for Shareholders
Warning to Shareholders
Terms of Reference & Policies
AIM Rule 26

Careers

Key Corporate Partnerships

Chi-Med
Innovation Platform
| Key Corporate Partnerships

AstraZeneca

In December 2011, Chi-Med entered into a global licensing, co-development, and commercialisation agreement regarding its highly selective c-Met inhibitor savolitinib with AstraZeneca.

Development costs for savolitinib in China are shared between Chi-Med and AstraZeneca, with Chi-Med continuing to lead the development in China. AstraZeneca leads and pays for the development of savolitinib for the rest of the world.

Chi-Med was entitled to receive an upfront payment as well as further payments contingent on the successful achievement of clinical development and first sale milestones.

The agreement also contains possible future commercial sale milestones, a fixed royalty of on all sales in China and double-digit tiered royalties on all sales made outside of China.

Eli Lilly

In October 2013, Chi-Med entered into a licensing, co-development and commercialisation agreement in China with Lilly for fruquintinib, a selective inhibitor of the vascular endothelial growth factor receptor tyrosine kinase.

Under the terms of the agreement, the costs of future development of fruquintinib in China, to be carried out by Chi-Med, will be shared between Chi-Med and Lilly.

Chi-Med has received upfront payments, as well as development and regulatory approval milestone payments. Chi-Med has also been receiving royalty payments since the late-Nov 2018 fruquintinib commercial launch.

In 2018, we entered into non-exclusive global collaboration agreements with Innovent and Junshi to conduct safety run-in studies to evaluate the safety of fruquintinib or surufatinib in combination with PD-1 monoclonal antibodies being developed by Innovent (Tyvyt) and Junshi (Tuoyi).

Innovent

Innovent Biologics is a biopharmaceutical company that discovers, develops and manufactures monoclonal antibodies for cancer and autoimmune diseases headquartered in Suzhou, China.

It has built up a pipeline of 20 drug assets, led by Tyvyt®(generic name: sintilimab, IBI-308), anti-PD-1 monoclonal antibody co-developed with Eli Lilly, which received marketing approval in China for relapsed or refractory classical Hodgkin lymphoma in late 2018.

In late November 2018, we entered into a global collaboration agreement with Innovent Biologics to evaluate the safety, tolerability and efficacy of fruquintinib in combination with their now commercial-stage drug Tyvyt®.

Junshi

Shanghai Junshi Biosciences is a biopharmaceutical company based in Shanghai, China that focuses on discovering, developing and commercializing innovative drugs.

Junshi has developed a product pipeline comprising 17 drug candidates, covering a wide variety of indications including immuno-oncology, metabolic diseases, inflammation or autoimmune diseases and neurologic diseases.

In late November 2018, we entered into a global collaboration agreement with Junshi to evaluate the safety, tolerability and efficacy of surufatinib in combination with their now commercial-stage drug Tuoyi® (generic name: toripalimab, JS001), a PD-1 monoclonal antibody approved in China for the treatment of melanoma in late 2018.

Contact Us
Disclaimer
Privacy Policy

© 2020 Hutchison China MediTech Limited